Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb

ResMed Inc. (RMD) reported robust fiscal Q4 2025 results, with adjusted EPS of $2.55, a 22.6% year-over-year increase, and revenues of $1.35 billion, up 10.2%, both surpassing analyst estimates. This strong performance was fueled by solid global demand for its sleep and breathing health devices and growth in Residential Care Software, while adjusted gross margins expanded 227 basis points to 61.4% due to cost efficiencies and currency tailwinds, leading to a 2.6% rise in RMD shares post-announcement.

Analysis

ResMed Inc. (RMD) reported a strong fourth quarter for fiscal 2025, demonstrating significant operational momentum and profitability gains. Adjusted EPS grew 22.6% year-over-year to $2.55, beating consensus estimates by 3.66%, while revenue increased 10.2% to $1.35 billion, also surpassing expectations. This top-line growth was broad-based, with the core Sleep and Breathing Health segment expanding 10.2% and the Residential Care Software segment growing 9.9%. Critically, the company achieved substantial margin expansion; the adjusted gross margin rose 227 basis points to 61.4% and the adjusted operating margin expanded 260 basis points to 35.3%, attributed to cost efficiencies and favorable currency movements. The balance sheet strengthened considerably, with the cash position increasing to $1.21 billion while total debt was reduced. The company's commitment to capital return was evident through $78 million in dividends and $100 million in share repurchases during the quarter, signaling management confidence. The market responded favorably, with the stock rising 2.6% in after-hours trading, though the report notes a neutral Zacks Rank #3 (Hold) rating.

Key Decisions for Investors

• Investors should view the dual beat on earnings and revenue, coupled with significant margin expansion, as a strong validation of ResMed's operational efficiency and market demand.
• It is critical to monitor the sustainability of the 227 bps gross margin improvement, assessing the ongoing impact of operational efficiencies versus the more volatile contribution from favorable currency movements.
• Given the positive after-hours stock movement and strong results, investors should weigh the company's fundamental momentum against its neutral Zacks #3 'Hold' rating, which may suggest the current valuation already reflects much of the positive news.
• Consider the robust capital return program, including $100 million in buybacks and consistent dividends, as a key component of total shareholder return and a signal of the company's strong cash flow generation and financial discipline.